You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIndapamide
Accession NumberDB00808  (APRD01031)
TypeSmall Molecule
GroupsApproved
Description

A benzamide-sulfonamide-indole. It is called a thiazide-like diuretic but structure is different enough (lacking the thiazo-ring) so it is not clear that the mechanism is comparable. [PubChem]

Structure
Thumb
Synonyms
Indapamid
Indapamida
Indapamide
Indapamidum
Metindamide
External Identifiers
  • RHC 2555
  • S 1520
  • SE 1520
  • USV 2555
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-indapamide Tablets 1.25mgtablet1.25 mgoralDominion Pharmacal1999-09-15Not applicableCanada
Dom-indapamide Tablets 2.5mgtablet2.5 mgoralDominion Pharmacal1999-09-15Not applicableCanada
Indapamidetablet2.5 mgoralSanis Health Inc2015-10-14Not applicableCanada
Indapamidetablet1.25 mgoralSanis Health Inc2015-10-14Not applicableCanada
Indapamidetablet2.5 mgoralSanis Health IncNot applicableNot applicableCanada
Indapamide Hemihydrate 1.25mg - Tabtablet1.25 mgoralProval Pharma Division Of Servier Canada Inc1997-08-142012-02-13Canada
Indapamide Hemihydrate Tab 2.5mgtablet2.5 mgoralProval Pharma Division Of Servier Canada Inc1995-12-312012-02-13Canada
Indapamide-2.5tablet2.5 mgoralPro Doc Limitee1997-04-302008-07-04Canada
Jamp-indapamidetablet2.5 mgoralJamp Pharma Corporation2011-10-17Not applicableCanada
Jamp-indapamidetablet1.25 mgoralJamp Pharma Corporation2011-10-17Not applicableCanada
Lozide - Tab 1.25mgtablet1.25 mgoralServier Canada Inc1995-12-31Not applicableCanada
Lozide Tab 2.5mgtablet2.5 mgoralServier Canada Inc1982-12-31Not applicableCanada
Mylan-indapamidetablet2.5 mgoralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Mylan-indapamidetablet1.25 mgoralMylan Pharmaceuticals Ulc1999-05-10Not applicableCanada
Ntp-indapamidetablet2.5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-indapamidetablet1.25 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-indapamide - Tab 2.5mgtablet2.5 mgoralNu Pharm Inc1996-08-292012-09-04Canada
PHL-indapamidetablet1.25 mgoralPharmel Inc2002-05-28Not applicableCanada
PHL-indapamidetablet2.5 mgoralPharmel Inc2002-05-28Not applicableCanada
PMS-indapamidetablet2.5 mgoralPharmascience Inc1999-02-18Not applicableCanada
PMS-indapamidetablet1.25 mgoralPharmascience Inc1999-02-18Not applicableCanada
Pro-indapamidetablet2.5 mgoralPro Doc Limitee2008-07-04Not applicableCanada
Pro-indapamidetablet1.25 mgoralPro Doc Limitee2008-07-04Not applicableCanada
Riva-indapamide 1.25tablet1.25 mgoralLaboratoire Riva Inc2003-03-11Not applicableCanada
Riva-indapamide 2.5 mgtablet2.5 mgoralLaboratoire Riva Inc2000-05-10Not applicableCanada
Teva-indapamidetablet2.5 mgoralTeva Canada Limited1997-05-04Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-indapamide 1.25 Mg Tabletstablet1.25 mgoralApotex Inc2002-11-08Not applicableCanada
Apo-indapamide 2.5mg Tabletstablet2.5 mgoralApotex Inc1996-10-02Not applicableCanada
Indapamidetablet, film coated2.5 mg/1oralbryant ranch prepack2007-01-02Not applicableUs
Indapamidetablet, film coated2.5 mg/1oralActavis Elizabeth LLC2007-01-02Not applicableUs
Indapamidetablet, film coated2.5 mg/1oralMylan Institutional Inc.1996-05-01Not applicableUs
Indapamidetablet2.5 mg/1oralREMEDYREPACK INC.2010-09-16Not applicableUs
Indapamidetablet, film coated2.5 mg/1oralAv Kare, Inc.2016-02-09Not applicableUs
Indapamidetablet, film coated1.25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-07-12Not applicableUs
Indapamidetablet, film coated1.25 mg/1oralAv Kare, Inc.2016-02-09Not applicableUs
Indapamidetablet, film coated1.25 mg/1oralRebel Distributors Corp2010-01-18Not applicableUs
Indapamidetablet, film coated2.5 mg/1oralMylan Pharmaceuticals Inc.1996-03-28Not applicableUs
Indapamidetablet, film coated1.25 mg/1oralMylan Pharmaceuticals Inc.1997-03-26Not applicableUs
Indapamidetablet, film coated1.25 mg/1oralCarilion Materials Management1997-03-26Not applicableUs
Indapamidetablet, film coated1.25 mg/1oralActavis Elizabeth LLC2007-01-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArifonServier
BajatenMerck
FludexServier
IndamolTeofarma
IpamixVisufarma
LozideServier
Lozolsanofi-aventis
NatrilixServier
NatrixKyoto Yakuhin
NoranatSandoz
TandixAzevedos
TertensifServier
VeroxilBaldacci
Brand mixtures
NameLabellerIngredients
Arcosyl PlusServier Canada Inc
Arcosyl Plus LdServier Canada Inc
Coversyl PlusServier Canada Inc
Coversyl Plus HdServier Canada Inc
Coversyl Plus LdServier Canada Inc
SaltsNot Available
Categories
UNIIF089I0511L
CAS number26807-65-8
WeightAverage: 365.835
Monoisotopic: 365.06008979
Chemical FormulaC16H16ClN3O3S
InChI KeyInChIKey=NDDAHWYSQHTHNT-UHFFFAOYSA-N
InChI
InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
IUPAC Name
4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzamide
SMILES
CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • 4-halobenzoic acid or derivatives
  • Benzenesulfonamide
  • Indole or derivatives
  • Benzoic acid or derivatives
  • Benzamide
  • Benzoyl
  • Halobenzene
  • Chlorobenzene
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Carboxylic acid hydrazide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of hypertension, alone or in combination with other antihypertensive drugs, as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy (appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed). Also used for the management of edema as a result of various causes.
PharmacodynamicsIndapamide is an antihypertensive and a diuretic. It contains both a polar sulfamoyl chlorobenzamide moiety and a lipid- soluble methylindoline moiety. Indapamide bears a structural similarity to the triazide diuretics which are known to decrease vascular smooth muscle reactivity. However, it differs chemically from the thiazides in that it does not possess the thiazide ring system and contains only one sulfonamide group. Indapamide appears to cause vasodilation, probably by inhibiting the passage of calcium and other ions (sodium, potassium) across membranes. This same effect may cause hypokalcemia in susceptible individuals. Indapamide has also been shown to cause uterine myometrial relaxation in experimental animals. Overall, indapamide has an extra-renal antihypertensive action resulting in a decrease in vascular hyperreactivity and a reduction in total peripheral and arteriolar resistance.
Mechanism of actionIndapamide blocks the slow component of delayed rectifier potassium current (IKs) without altering the rapid component (IKr) or the inward rectifier current. Specifically it blocks or antagonizes the action the proteins KCNQ1 and KCNE1. Indapamide is also thought to stimulate the synthesis of the vasodilatory hypotensive prostaglandin PGE2.
Related Articles
AbsorptionRapidly absorbed from gastrointestinal tract.
Volume of distributionNot Available
Protein binding71-79%
Metabolism

Primarily hepatic. Indapamide is an extensively metabolized drug with only about 7+ACU- of the total dose administered, recovered in the urine as unchanged drug during the first 48 hours after administration.

SubstrateEnzymesProduct
Indapamide
Indapamide metabolite M5Details
Indapamide metabolite M5
Indapamide metabolite M4Details
Indapamide metabolite M4
Not Available
Indapamide metabolite M2Details
Indapamide
Indapamide metabolite M1Details
Indapamide metabolite M1
Indapamide metabolite M3Details
Indapamide metabolite M3
Indapamide metabolite M2Details
Indapamide
Indapamide epoxide intermediateDetails
Indapamide epoxide intermediate
Indapamide metabolite M6Details
Route of eliminationIndapamide is an extensively metabolized drug, with only about 7% of the total dose administered, recovered in the urine as unchanged drug during the first 48 hours after administration.
Half life14 hours (biphasic)
ClearanceNot Available
ToxicitySide effects include electrolyte imbalance (potassium or salt depletion due to too much fluid loss), nausea, stomach disorders, vomiting, weakness
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Indapamide Action PathwayDrug actionSMP00110
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8868
Caco-2 permeable-0.5529
P-glycoprotein substrateNon-substrate0.6859
P-glycoprotein inhibitor INon-inhibitor0.9158
P-glycoprotein inhibitor IINon-inhibitor0.9179
Renal organic cation transporterNon-inhibitor0.8575
CYP450 2C9 substrateNon-substrate0.5265
CYP450 2D6 substrateNon-substrate0.7924
CYP450 3A4 substrateNon-substrate0.519
CYP450 1A2 substrateInhibitor0.582
CYP450 2C9 inhibitorNon-inhibitor0.5775
CYP450 2D6 inhibitorNon-inhibitor0.8151
CYP450 2C19 inhibitorNon-inhibitor0.6572
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7471
Ames testNon AMES toxic0.6869
CarcinogenicityNon-carcinogens0.7674
BiodegradationNot ready biodegradable0.9862
Rat acute toxicity2.0823 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.986
hERG inhibition (predictor II)Non-inhibitor0.8804
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Cadista pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tabletoral2.5 mg/1
Tablet, film coatedoral1.25 mg/1
Tablet, film coatedoral2.5 mg/1
Tabletoral1.25 mg
Tabletoral2.5 mg
Prices
Unit descriptionCostUnit
Indapamide 2.5 mg tablet0.85USD tablet
Indapamide 1.25 mg tablet0.69USD tablet
Lozide 2.5 mg Tablet0.55USD tablet
Apo-Indapamide 2.5 mg Tablet0.31USD tablet
Mylan-Indapamide 2.5 mg Tablet0.31USD tablet
Novo-Indapamide 2.5 mg Tablet0.31USD tablet
Nu-Indapamide 2.5 mg Tablet0.31USD tablet
Pms-Indapamide 2.5 mg Tablet0.31USD tablet
Apo-Indapamide 1.25 mg Tablet0.2USD tablet
Mylan-Indapamide 1.25 mg Tablet0.2USD tablet
Pms-Indapamide 1.25 mg Tablet0.2USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point160-162U.S.Patent 3,565,911.
water solubility75 mg/LNot Available
logP2.2Not Available
pKa8.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0342 mg/mLALOGPS
logP2.52ALOGPS
logP2.64ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)8.85ChemAxon
pKa (Strongest Basic)0.097ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.5 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity103.31 m3·mol-1ChemAxon
Polarizability36.34 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Chunyi Yeh, Yi-Lung Wang, Ya-Sheng Yang, Ya-Ching Chang Chein, “Oral sustained-release pharmaceutical composition of indapamide, production and use thereof.” U.S. Patent US20060182803, issued August 17, 2006.

US20060182803
General References
  1. Dong DL, Wang QH, Yue P, Jiao JD, Gu RM, Yang BF: Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84. Epub 2006 Mar 2. [PubMed:16556441 ]
External Links
ATC CodesC03BA11C09BX01
AHFS Codes
  • 40:28.24
PDB EntriesNot Available
FDA labelDownload (322 KB)
MSDSDownload (72.7 KB)
Interactions
Drug Interactions
Drug
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Indapamide.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Indapamide.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Indapamide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Indapamide.
AlfuzosinAlfuzosin may increase the hypotensive activities of Indapamide.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Indapamide.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Indapamide.
AmifostineIndapamide may increase the hypotensive activities of Amifostine.
BrimonidineBrimonidine may increase the antihypertensive activities of Indapamide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Indapamide.
ButabarbitalButabarbital may increase the orthostatic hypotensive activities of Indapamide.
ButethalButethal may increase the orthostatic hypotensive activities of Indapamide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Indapamide.
CaffeineThe risk or severity of adverse effects can be increased when Caffeine is combined with Indapamide.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indapamide.
CarbamazepineThe risk or severity of adverse effects can be increased when Indapamide is combined with Carbamazepine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Indapamide.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Indapamide.
CitalopramIndapamide may increase the QTc-prolonging activities of Citalopram.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Indapamide.
ColesevelamColesevelam can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclophosphamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Cyclophosphamide.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Indapamide.
DiazoxideThe risk or severity of adverse effects can be increased when Indapamide is combined with Diazoxide.
DigoxinThe risk or severity of adverse effects can be increased when Indapamide is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Indapamide.
DihydrotachysterolIndapamide may increase the hypercalcemic activities of Dihydrotachysterol.
DofetilideIndapamide may increase the QTc-prolonging activities of Dofetilide.
DuloxetineIndapamide may increase the orthostatic hypotensive activities of Duloxetine.
EthanolEthanol may increase the orthostatic hypotensive activities of Indapamide.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Indapamide.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Indapamide.
FlunisolideFlunisolide may increase the hypokalemic activities of Indapamide.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Indapamide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Indapamide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Indapamide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Indapamide.
GoserelinIndapamide may increase the QTc-prolonging activities of Goserelin.
HeptabarbitalHeptabarbital may increase the orthostatic hypotensive activities of Indapamide.
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Indapamide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Indapamide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Indapamide.
InfliximabThe therapeutic efficacy of Indapamide can be decreased when used in combination with Infliximab.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Indapamide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Indapamide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Indapamide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Indapamide.
Insulin HumanThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Indapamide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Indapamide.
IvabradineIndapamide may increase the arrhythmogenic activities of Ivabradine.
LeuprolideIndapamide may increase the QTc-prolonging activities of Leuprolide.
LevodopaIndapamide may increase the orthostatic hypotensive activities of Levodopa.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Indapamide.
LicoriceLicorice may increase the hypokalemic activities of Indapamide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Indapamide.
LithiumIndapamide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
MecamylamineThe risk or severity of adverse effects can be increased when Indapamide is combined with Mecamylamine.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Indapamide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Indapamide.
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Indapamide.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Indapamide.
MifepristoneMifepristone may increase the QTc-prolonging activities of Indapamide.
MolsidomineMolsidomine may increase the hypotensive activities of Indapamide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Indapamide.
MoxonidineMoxonidine may increase the hypotensive activities of Indapamide.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Indapamide.
NicorandilNicorandil may increase the hypotensive activities of Indapamide.
ObinutuzumabIndapamide may increase the hypotensive activities of Obinutuzumab.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Indapamide.
OxcarbazepineThe risk or severity of adverse effects can be increased when Indapamide is combined with Oxcarbazepine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Indapamide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Indapamide.
ParoxetineParoxetine may increase the activities of Indapamide.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Indapamide.
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Indapamide.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Indapamide.
PerindoprilIndapamide may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Indapamide.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Indapamide.
PorfimerIndapamide may increase the photosensitizing activities of Porfimer.
PrimidonePrimidone may increase the orthostatic hypotensive activities of Indapamide.
ProcyclidineThe serum concentration of Indapamide can be increased when it is combined with Procyclidine.
QuinineQuinine may increase the hypotensive activities of Indapamide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Indapamide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Indapamide.
RisperidoneIndapamide may increase the hypotensive activities of Risperidone.
RituximabIndapamide may increase the hypotensive activities of Rituximab.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Indapamide.
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Indapamide.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Indapamide.
SulpirideThe risk or severity of adverse effects can be increased when Indapamide is combined with Sulpiride.
TadalafilTadalafil may increase the antihypertensive activities of Indapamide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Indapamide.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Indapamide.
TopiramateIndapamide may increase the hypokalemic activities of Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Indapamide.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Indapamide.
TreprostinilTreprostinil may increase the hypotensive activities of Indapamide.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Indapamide.
VardenafilVardenafil may increase the antihypertensive activities of Indapamide.
VerteporfinIndapamide may increase the photosensitizing activities of Verteporfin.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Indapamide.
YohimbineYohimbine may decrease the antihypertensive activities of Indapamide.
Food Interactions
  • Take without regard to meals. Magnesium, potassium and zinc needs increased.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Potassium channel that plays an important role in a number of tissues, including heart, inner ear, stomach and colon (By similarity) (PubMed:10646604). Associates with KCNE beta subunits that modulates current kinetics (By similarity) (PubMed:9312006, PubMed:9108097, PubMed:8900283, PubMed:10646604, PubMed:11101505, PubMed:19687231). Induces a voltage-dependent by rapidly activating and slowly ...
Gene Name:
KCNQ1
Uniprot ID:
P51787
Molecular Weight:
74697.925 Da
References
  1. Ohya S, Asakura K, Muraki K, Watanabe M, Imaizumi Y: Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G277-87. [PubMed:11804849 ]
  2. Li RA, Miake J, Hoppe UC, Johns DC, Marban E, Nuss HB: Functional consequences of the arrhythmogenic G306R KvLQT1 K+ channel mutant probed by viral gene transfer in cardiomyocytes. J Physiol. 2001 May 15;533(Pt 1):127-33. [PubMed:11351021 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Telethonin binding
Specific Function:
Ancillary protein that assembles as a beta subunit with a voltage-gated potassium channel complex of pore-forming alpha subunits. Modulates the gating kinetics and enhances stability of the channel complex. Assembled with KCNB1 modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 (PubMed:19219384). Assembled with KCNQ1/KVLQT1 is proposed to for...
Gene Name:
KCNE1
Uniprot ID:
P15382
Molecular Weight:
14674.66 Da
References
  1. Ohya S, Asakura K, Muraki K, Watanabe M, Imaizumi Y: Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G277-87. [PubMed:11804849 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Sun H, Moore C, Dansette PM, Kumar S, Halpert JR, Yost GS: Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions. Drug Metab Dispos. 2009 Mar;37(3):672-84. doi: 10.1124/dmd.108.022707. Epub 2008 Dec 12. [PubMed:19074530 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on November 14, 2013 10:19